Biogen Inc.
www.biogen.com
Latest From Biogen Inc.
GemVax's Novel Peptide For Alzheimer’s Set To Advance After Positive Phase II
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.
Keeping Track Of Thanksgiving Leftovers: Risdiplam, Artesunate Highlight Glut Of Submissions/Filings
Yes, we know they should be out of the fridge by now, but here are the highlights of submissions and filings during the Thanksgiving week.
Aurinia Closing In On Lupus Nephritis With Voclosporin
Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.
Concerns Emerge Over England’s Desire For Even Lower Drug Prices
With the emphasis on getting lower prices even for cost-effective drugs, England’s proposed commercial framework may be sending a negative signal to global companies.
Company Information
- Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Cancer
- Cardiovascular
- Immune Disorders
- Inflammation
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alias(es)
- Biogen Idec Inc.
- Biogen Inc.
- Idec Pharmaceutical Corp.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Biogen Inc.
- Senior Management
-
Michel Vounatsos, CEO
Jeffrey Capello, EVP, CFO
Alfred W Sandrock, Jr., MD, PhD, EVP, R&D & CMO
Daniel Karp, EVP, Corp. Dev.
Chirfi Guindo, EVP & Head, Global Mktg. - Contact Info
-
Biogen Inc.
Phone: (617) 679-2000
225 Binney St.
Cambridge, MA 02142
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice